1st NICOTINE PATCH LAUNCHED IN UK
Ciba-Geigy has launched the first transdermal nicotine patch, Nicotinell TTS, to reach the UK smoking cessation market. The patch will be available on prescription-only, and it is likely that the product will not be reimbursable. Ciba-Geigy says that it is considering an appeal against this decision, but for the moment is recommending that physicians write private prescriptions for the product.
The main rival to Nicotinell in the UK at the moment is Nicorette, a chewing gum marketed by Lundbeck which Ciba-Geigy says is more difficult to use than patch systems. Medical Director at Ciba-Geigy, John Domenet, said that Nicotinell, designed to be taken in a three-month course, gradually weans smokers off cigarettes by alleviating their physical dependency on nicotine.
Ciba-Geigy is also providing a comprehensive patient support package, consisting of an advice booklet, videos and a free telephone counselling line, which is designed to allow use of the patch with little or no counselling from the GP.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze